JP2023503374A - 新規なペプチドと多糖類とのコンジュゲート - Google Patents

新規なペプチドと多糖類とのコンジュゲート Download PDF

Info

Publication number
JP2023503374A
JP2023503374A JP2022532756A JP2022532756A JP2023503374A JP 2023503374 A JP2023503374 A JP 2023503374A JP 2022532756 A JP2022532756 A JP 2022532756A JP 2022532756 A JP2022532756 A JP 2022532756A JP 2023503374 A JP2023503374 A JP 2023503374A
Authority
JP
Japan
Prior art keywords
lys
hyp
dopa
tyr
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022532756A
Other languages
English (en)
Japanese (ja)
Inventor
グ、ミン
ソン、マオチャン
ジャンソン、ジャン-クリスター
インゲマール サミュエルソン、ベングト
Original Assignee
エンリティザ(シャンハイ)ファーマシューティカル カンパニー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エンリティザ(シャンハイ)ファーマシューティカル カンパニー リミテッド filed Critical エンリティザ(シャンハイ)ファーマシューティカル カンパニー リミテッド
Publication of JP2023503374A publication Critical patent/JP2023503374A/ja
Priority to JP2026005938A priority Critical patent/JP2026067913A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J3/00—Processes of treating or compounding macromolecular substances
    • C08J3/02—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques
    • C08J3/03—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques in aqueous media
    • C08J3/075—Macromolecular gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J2305/00—Characterised by the use of polysaccharides or of their derivatives not provided for in groups C08J2301/00 or C08J2303/00
    • C08J2305/08—Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J2389/00—Characterised by the use of proteins; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Birds (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Polymers & Plastics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Otolaryngology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Materials Engineering (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
JP2022532756A 2019-12-02 2020-12-02 新規なペプチドと多糖類とのコンジュゲート Pending JP2023503374A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026005938A JP2026067913A (ja) 2019-12-02 2026-01-16 新規なペプチドと多糖類とのコンジュゲート

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2019/122391 2019-12-02
CNPCT/CN2019/122391 2019-12-02
PCT/CN2020/133438 WO2021110063A1 (en) 2019-12-02 2020-12-02 New conjugates of peptides and polysaccharide

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026005938A Division JP2026067913A (ja) 2019-12-02 2026-01-16 新規なペプチドと多糖類とのコンジュゲート

Publications (1)

Publication Number Publication Date
JP2023503374A true JP2023503374A (ja) 2023-01-27

Family

ID=76221459

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2022532756A Pending JP2023503374A (ja) 2019-12-02 2020-12-02 新規なペプチドと多糖類とのコンジュゲート
JP2022532785A Active JP7895852B2 (ja) 2019-12-02 2020-12-02 ペプチド及び炎症の治療におけるそれらの使用
JP2026005938A Pending JP2026067913A (ja) 2019-12-02 2026-01-16 新規なペプチドと多糖類とのコンジュゲート

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022532785A Active JP7895852B2 (ja) 2019-12-02 2020-12-02 ペプチド及び炎症の治療におけるそれらの使用
JP2026005938A Pending JP2026067913A (ja) 2019-12-02 2026-01-16 新規なペプチドと多糖類とのコンジュゲート

Country Status (9)

Country Link
US (2) US20240218016A1 (cg-RX-API-DMAC7.html)
EP (2) EP4069713A4 (cg-RX-API-DMAC7.html)
JP (3) JP2023503374A (cg-RX-API-DMAC7.html)
KR (2) KR20220117256A (cg-RX-API-DMAC7.html)
CN (2) CN114929726A (cg-RX-API-DMAC7.html)
AU (2) AU2020396818A1 (cg-RX-API-DMAC7.html)
CA (2) CA3160127A1 (cg-RX-API-DMAC7.html)
TW (2) TW202133882A (cg-RX-API-DMAC7.html)
WO (2) WO2021110063A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4028409A4 (en) 2019-09-14 2023-10-11 EnliTISA (Shanghai) Pharmaceutical Co., Ltd. NEW PEPTIDES
JP2026506026A (ja) * 2023-02-13 2026-02-20 エンリティザ(シャンハイ)ファーマシューティカル カンパニー リミテッド 新規多機能オリゴペプチド
AU2024312518A1 (en) * 2023-06-22 2026-01-22 Enlitisa (Shanghai) Pharmaceutical Co., Ltd. New multi-functional oligopeptides
WO2025195444A1 (en) 2024-03-20 2025-09-25 Enlitisa (Shanghai) Pharmaceutical Co., Ltd. New use of peptides derived from vasoactive intestinal peptide

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5229490A (en) * 1987-05-06 1993-07-20 The Rockefeller University Multiple antigen peptide system
WO2000015789A1 (en) * 1998-09-09 2000-03-23 United States Surgical Corporation Recombinant bioadhesive protein analogs comprising hydroxyproline
JP2004508338A (ja) * 2000-09-08 2004-03-18 グリフォン セラピューティクス,インコーポレーテッド ポリマー修飾合成タンパク質
JP2004513897A (ja) * 2000-11-03 2004-05-13 セントロ デ インジエニエリア ジエネテイカ イ バイオテクノロジア 特定交叉反応性を高める抗原構造を得る方法
WO2007124593A1 (en) * 2006-05-02 2007-11-08 Universite Laval Branched peptide amplification and uses thereof
JP2018513879A (ja) * 2015-04-17 2018-05-31 サイミック アイピー, エルエルシー バイオコンジュゲートおよびその使用
WO2018100174A1 (en) * 2016-12-02 2018-06-07 Sanofi Conjugates comprising an glp-1/glucagon dual agonist, a linker and hyaluronic acid
WO2019007355A1 (en) * 2017-07-05 2019-01-10 Jiangyin Usun Pharmaceutical Co., Ltd. ANTI-INFLAMMATORY USE OF PEPTIDE
WO2019173777A1 (en) * 2018-03-09 2019-09-12 Valitor, Inc. Multivalent peptide conjugates for sustained intra-articular treatment of joint inflammation

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02500082A (ja) * 1987-03-12 1990-01-18 ジェネックス・コーポレーション 遺伝子操作された生物による生物粘着物質前駆体タンパク質類似体の生産
US4908404A (en) * 1988-08-22 1990-03-13 Biopolymers, Inc. Synthetic amino acid-and/or peptide-containing graft copolymers
US5616311A (en) * 1991-01-15 1997-04-01 Hemosphere, Inc. Non-crosslinked protein particles for therapeutic and diagnostic use
EP0831793A4 (en) * 1995-06-06 2000-11-15 Hemosphere Inc PROTEIN PARTICLES FOR THERAPEUTIC AND DIAGNOSTIC USE
JP5133048B2 (ja) * 2004-02-27 2013-01-30 ノースウエスタン ユニバーシティ 重合化合物及び関連した使用方法
WO2009001220A2 (en) * 2007-06-26 2008-12-31 Universitetet I Oslo Functionalization of microscopy probe tips
US20130224269A1 (en) * 2010-11-15 2013-08-29 Avon Products, Inc. Biofunctional Anchored Extended-Wear Cosmetics
JP6202669B2 (ja) * 2013-04-26 2017-09-27 国立研究開発法人国立循環器病研究センター ペプチド及びその複合体、組織修復用スキャフォールド及びその表面処理方法、並びに表面処理液又は処理液のセット
KR101677097B1 (ko) * 2015-03-18 2016-11-18 포항공과대학교 산학협력단 내부 장기의 접합 및 누공, 천공 또는 문합부 누출 치료용 접착 실란트
KR102468524B1 (ko) * 2015-07-20 2022-11-18 장인 벵트 아이. 사무엘손 인스티튜트 오브 라이프 사이언스 컴퍼니 리미티드 멜라닌과 관련된 질환의 치료 및 예방에서의 홍합 접착 단백질 제품의 용도
BR112018000953A2 (pt) * 2015-07-20 2018-09-11 Bengt I. Samuelsson Institute Of Life Science Research produto de proteína adesiva de mexilhão e aplicações do mesmo na supressão de inflamações de pele
WO2017028025A1 (zh) * 2015-08-14 2017-02-23 江阴市本特塞缪森生命科学研究院有限公司 贻贝粘蛋白产品及其抑制粘膜炎症的应用
WO2017088177A1 (zh) * 2015-11-27 2017-06-01 江阴市本特塞缪森生命科学研究院有限公司 贻贝粘蛋白产品及其预防和抑制神经炎症的应用
KR101807593B1 (ko) * 2015-12-30 2017-12-11 포항공과대학교 산학협력단 흉터 최소화 상처 재생 촉진용 재조합 폴리펩타이드 및 이를 포함하는 생체 접착 소재
CA3068818A1 (en) * 2017-07-05 2019-01-10 Jiangyin Mucocare Pharmaceutical Co., Ltd Topical formulations comprising montelukast and combinations with mussel adhesive proteins
KR102010051B1 (ko) * 2017-09-20 2019-08-12 주식회사 포스코 카테콜 치환된 음이온성 고분자로부터 형성된 코아세르베이트, 이를 포함하는 접착제 및 이의 제조방법
MA52794A (fr) * 2018-05-28 2021-04-14 Jiangyin Usun Pharmaceutical Co Ltd Nouvelle utilisation pharmaceutique
HUE062848T2 (hu) * 2018-09-14 2023-12-28 Enlitisa Shanghai Pharmaceutical Co Ltd Montelukaszt és peptidek konjugátumai

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5229490A (en) * 1987-05-06 1993-07-20 The Rockefeller University Multiple antigen peptide system
WO2000015789A1 (en) * 1998-09-09 2000-03-23 United States Surgical Corporation Recombinant bioadhesive protein analogs comprising hydroxyproline
JP2004508338A (ja) * 2000-09-08 2004-03-18 グリフォン セラピューティクス,インコーポレーテッド ポリマー修飾合成タンパク質
JP2004513897A (ja) * 2000-11-03 2004-05-13 セントロ デ インジエニエリア ジエネテイカ イ バイオテクノロジア 特定交叉反応性を高める抗原構造を得る方法
WO2007124593A1 (en) * 2006-05-02 2007-11-08 Universite Laval Branched peptide amplification and uses thereof
JP2018513879A (ja) * 2015-04-17 2018-05-31 サイミック アイピー, エルエルシー バイオコンジュゲートおよびその使用
WO2018100174A1 (en) * 2016-12-02 2018-06-07 Sanofi Conjugates comprising an glp-1/glucagon dual agonist, a linker and hyaluronic acid
WO2019007355A1 (en) * 2017-07-05 2019-01-10 Jiangyin Usun Pharmaceutical Co., Ltd. ANTI-INFLAMMATORY USE OF PEPTIDE
WO2019173777A1 (en) * 2018-03-09 2019-09-12 Valitor, Inc. Multivalent peptide conjugates for sustained intra-articular treatment of joint inflammation

Also Published As

Publication number Publication date
JP2026067913A (ja) 2026-04-21
EP4069715A1 (en) 2022-10-12
TW202133882A (zh) 2021-09-16
EP4069713A1 (en) 2022-10-12
JP7895852B2 (ja) 2026-07-28
EP4069713A4 (en) 2024-10-02
KR20220116468A (ko) 2022-08-23
JP2023503380A (ja) 2023-01-27
CA3160167A1 (en) 2021-06-10
CN114929283A (zh) 2022-08-19
WO2021110063A1 (en) 2021-06-10
WO2021110063A8 (en) 2022-05-05
AU2020396818A1 (en) 2022-06-30
EP4069715A4 (en) 2024-08-14
WO2021110061A1 (en) 2021-06-10
US20230113836A1 (en) 2023-04-13
CN114929726A (zh) 2022-08-19
TW202128729A (zh) 2021-08-01
AU2020396109A1 (en) 2022-07-07
US20240218016A1 (en) 2024-07-04
CA3160127A1 (en) 2021-06-10
KR20220117256A (ko) 2022-08-23

Similar Documents

Publication Publication Date Title
KR102946621B1 (ko) 몬테루카스트와 펩티드의 새로운 접합체
TWI913236B (zh) 新多功能寡肽
JP2026000993A (ja) 新ペプチド
JP2026067913A (ja) 新規なペプチドと多糖類とのコンジュゲート
WO2024169972A1 (en) New multi-functional oligopeptides
JP2024511369A (ja) 新規のペプチドコンジュゲート
WO2024260465A1 (en) New multi-functional oligopeptides
WO2025087269A1 (en) New short-chain peptides and derivatives thereof

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231130

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241224

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250319

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250623

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250916

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260116